ALT - רווח נקי למניה (EPS TTM) Altimmune

Altimmune, Inc. (ALT) is actively developing pemvidutide, offering an effective solution for weight loss while preserving muscle mass. The company leverages its own peptide ecosystem to create a unique therapeutic circuit. On GURU.Markets, the company's rolling annual per-share profit confirms the quality of the business, with the indicator value standing at -0.79. Stability of development is ensured by precise pharmaceutical logistics, guaranteeing the safety of all clinical trials.

Net income per share over 12 months determines the real return on each unit of capital, allowing for an assessment of the business's internal resilience to market volatility. For the R&D-intensive Altimmune, Inc. (ALT), which invests in peptide development and a costly staff of endocrinologists, the rolling annual earnings per share verifies the efficiency of clinical trial cost management relative to the volume of issuance.